Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID is a synthetic small molecule and an experimental drug candidate that functions as a potent and specific inhibitor of arginase. Arginase is an enzyme that catalyzes the hydrolysis of L-arginine into L-ornithine and urea. By inhibiting arginase, this compound increases the bioavailability of L-arginine, which is a substrate for nitric oxide synthase (NOS) to produce nitric oxide (NO). Elevated arginase activity is implicated in various pathological conditions, and its inhibition can restore NO production, leading to potential therapeutic benefits. Research has explored its use in preclinical models for conditions such as chronic obstructive pulmonary disease (COPD), allergic asthma, erectile dysfunction, and bacterial infections like those caused by Bacillus anthracis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID.